companiesCompany
TScan Therapeutics
TCR discovery company that cut 75% of staff in September 2026 to focus on in vivo-engineered TCR-T for solid tumours (PRAME, MAGE-A4).
Paused the phase 3 ALLOHA-2 trial of TSC-101 for lack of capital; two in vivo TCR-T candidates (PRAME, MAGE-A4) entering IND-enabling studies with phase 1 planned Q4 2027. Previously ran a multiplexed autologous TCR-T basket study in solid tumours.